Syros Pharmaceuticals, Inc.
SYRSDelisted Mar 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001556263
Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.
Holders of 5% or more of SYRS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Syros Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avidity Partners Management LP | 13G/A | 7.60%2.05M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Syros Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20256:17 PM ET | Samsara BioCapital, L.P.and 2 others | 13D/A | 2.60%707.1K shares | –Below 5% | Nov 18, 2024 | SEC |
| Feb 14, 20254:09 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 0.00%496 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 202510:10 AM ET | Avidity Partners Management LPand 7 others | 13G/A | 7.60%2.05M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20258:41 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 20254:30 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 3.80%1.06M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 20259:41 AM ET | Adage Capital Partners GP, L.L.C.and 3 others | 13G/A | 1.98%531.9K shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Syros Pharmaceuticals, Inc. shares.
No Form 144 notices for Syros Pharmaceuticals, Inc. are on file.